5 Results for "

STAT3 degrader-1

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "STAT3 degrader-1" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-147048
CAS No.: 2497585-16-5
Target:  

STAT

Research Areas:  

Cancer

STAT3 degrader-1 is a small-molecule targeted protein degrader that targets STAT3. STAT3 degrader-1 is applicable to studies on STAT3-dependent signaling pathways and leukemia [1].
loading...
    loading...
Cat. No.: HY-158142
CAS No.: 2770470-20-5
Purity:  99.46%
Target:  

PROTACs JAK STAT

Research Areas:  

Inflammation/Immunology Cancer

PROTAC TYK2 degrader-1 is a TYK2 PROTAC degrader with a Dmax ≥ 60%. PROTAC TYK2 degrader-1 reduces the phosphorylation levels of IFNα-induced STAT1 (Tyr701) and STAT3 (Tyr705) in immune cells. PROTAC TYK2 degrader-1 can be used in research on cancer, inflammatory diseases, etc. [1]
loading...
    loading...
Cat. No.: HY-169370
CAS No.: 2767166-30-1
Target:  

STAT

STAT3 HiBiT degrader 1 is a STAT3 HiBiT degrader with a DC50 of less than 0.05 μM in A549 cells [1].
loading...
    loading...
Cat. No.: HY-175849
Research Areas:  

Cancer

ALK degrader 1 is a potent, hydrophobic tag (HyT)-based degrader that induces ubiquitin-proteasome system (UPS)-dependent EML4-ALK degradation (DC50 = 0.13 μM). ALK degrader 1 demonstrates potent ALK degradation and antiproliferative effects in ALK-dependent cell lines, while showing minimal cytotoxicity in ALK fusion-negative cells. ALK degrader 1 triggers cell cycle arrest at the G0/G1 phase and stimulates apoptosis. ALK degrader 1 not only facilitates efficient degradation of the ALK protein but also disrupts key downstream effectors, including the STAT3 signaling axis. ALK degrader 1 mediates robust EML4-ALK degradation in vivo. ALK degrader 1 can be used for ALK-related diseases research [1].
loading...
    loading...
Cat. No.: HY-179715
PROTAC JAK1/2 degrader-1 is an orally active JAK1/JAK2 PROTAC degrader, with DC50 values of 1.4 μM and 0.92 μM against JAK1 and JAK2, respectively. PROTAC JAK1/2 degrader-1 triggers degradation via a CRBN- and proteasome-dependent pathway. PROTAC JAK1/2 degrader-1 inhibits the secretion of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). PROTAC JAK1/2 degrader-1 alleviates inflammatory responses and colon injury by inhibiting the JAK/STAT3 signaling pathway. PROTAC JAK1/2 degrader-1 can be used for the research of inflammatory bowel disease [1].
loading...
    loading...